Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters.

Schindler CW, Thorndike EB, Rice KC, Partilla JS, Baumann MH.

J Pharmacol Exp Ther. 2019 Jun;369(3):328-336. doi: 10.1124/jpet.118.255976. Epub 2019 Mar 21.

2.

The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates.

Saha K, Li Y, Holy M, Lehner KR, Bukhari MO, Partilla JS, Sandtner W, Sitte HH, Baumann MH.

Psychopharmacology (Berl). 2019 Mar;236(3):953-962. doi: 10.1007/s00213-018-5075-5. Epub 2018 Oct 22.

PMID:
30345459
3.

The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes.

Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, Rothman RB.

Psychopharmacology (Berl). 2019 Mar;236(3):915-924. doi: 10.1007/s00213-018-5063-9. Epub 2018 Oct 20.

PMID:
30341459
4.

Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH.

Neuropharmacology. 2018 Nov;142:240-250. doi: 10.1016/j.neuropharm.2018.02.033. Epub 2018 Mar 1.

5.

Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family.

Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, Kavanagh PV, Sandtner W, Blough BE, Brandt SD, Baumann MH, Sitte HH.

Neuropharmacology. 2018 May 15;134(Pt A):149-157. doi: 10.1016/j.neuropharm.2017.10.006. Epub 2017 Oct 6.

6.

Cocaine-like discriminative stimulus effects of "norepinephrine-preferring" monoamine releasers: time course and interaction studies in rhesus monkeys.

Kohut SJ, Jacobs DS, Rothman RB, Partilla JS, Bergman J, Blough BE.

Psychopharmacology (Berl). 2017 Dec;234(23-24):3455-3465. doi: 10.1007/s00213-017-4731-5. Epub 2017 Sep 9.

7.

N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Solis E Jr, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH.

Neuropsychopharmacology. 2017 Sep;42(10):1950-1961. doi: 10.1038/npp.2017.98. Epub 2017 May 22.

8.

Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers.

McLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Murphy B, Walther D, Partilla JS, Baumann MH, Brandt SD.

Drug Test Anal. 2017 Mar;9(3):347-357. doi: 10.1002/dta.2167. Epub 2017 Mar 7.

9.

Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats.

Elmore JS, Dillon-Carter O, Partilla JS, Ellefsen KN, Concheiro M, Suzuki M, Rice KC, Huestis MA, Baumann MH.

Neuropsychopharmacology. 2017 Feb;42(3):649-660. doi: 10.1038/npp.2016.213. Epub 2016 Sep 23.

10.

Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone.

McLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Talbot B, Walther D, Partilla JS, Baumann MH, Brandt SD.

Drug Test Anal. 2017 Mar;9(3):358-368. doi: 10.1002/dta.2053. Epub 2016 Sep 21.

11.

Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters.

Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt NV, Mihovilovic MD, Baumann MH, Sitte HH.

Br J Pharmacol. 2016 Sep;173(17):2657-68. doi: 10.1111/bph.13547. Epub 2016 Jul 31.

12.

Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats.

Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, Negus SS.

Eur Neuropsychopharmacol. 2016 Feb;26(2):288-297. doi: 10.1016/j.euroneuro.2015.12.010. Epub 2015 Dec 11.

13.

Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters.

Sandtner W, Stockner T, Hasenhuetl PS, Partilla JS, Seddik A, Zhang YW, Cao J, Holy M, Steinkellner T, Rudnick G, Baumann MH, Ecker GF, Newman AH, Sitte HH.

Mol Pharmacol. 2016 Jan;89(1):165-75. doi: 10.1124/mol.115.101394. Epub 2015 Oct 30.

14.

The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.

Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH.

Neuropharmacology. 2016 Feb;101:68-75. doi: 10.1016/j.neuropharm.2015.09.004. Epub 2015 Sep 8.

15.
16.

Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters.

Kolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA.

ACS Chem Neurosci. 2015 Oct 21;6(10):1726-31. doi: 10.1021/acschemneuro.5b00160. Epub 2015 Aug 11.

17.

Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.

Rothman RB, Ananthan S, Partilla JS, Saini SK, Moukha-Chafiq O, Pathak V, Baumann MH.

J Pharmacol Exp Ther. 2015 Jun;353(3):529-38. doi: 10.1124/jpet.114.222299. Epub 2015 Mar 18.

18.

Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats.

Kolanos R, Partilla JS, Baumann MH, Hutsell BA, Banks ML, Negus SS, Glennon RA.

ACS Chem Neurosci. 2015 May 20;6(5):771-7. doi: 10.1021/acschemneuro.5b00006. Epub 2015 Mar 3.

19.

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL.

Drug Alcohol Depend. 2015 Feb 1;147:1-19. doi: 10.1016/j.drugalcdep.2014.12.005. Epub 2014 Dec 18. Review.

20.

Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues.

Sakloth F, Kolanos R, Mosier PD, Bonano JS, Banks ML, Partilla JS, Baumann MH, Negus SS, Glennon RA.

Br J Pharmacol. 2015 May;172(9):2210-8. doi: 10.1111/bph.13043. Epub 2015 Feb 27.

21.

'Second-generation' mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function.

Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, Baumann MH.

Neuropsychopharmacology. 2015 May;40(6):1321-31. doi: 10.1038/npp.2014.325. Epub 2014 Dec 15.

22.

Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues.

Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, Cozzi NV, Partilla JS, Baumann MH, Negus SS.

Br J Pharmacol. 2015 May;172(10):2433-44. doi: 10.1111/bph.13030. Epub 2015 Apr 10.

23.

Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR).

McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Mahony O, Brandt SD, Patrick J, Archer RP, Partilla JS, Baumann MH.

Drug Test Anal. 2015 Jul;7(7):555-64. doi: 10.1002/dta.1732. Epub 2014 Oct 20.

24.

Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats.

Gregg RA, Baumann MH, Partilla JS, Bonano JS, Vouga A, Tallarida CS, Velvadapu V, Smith GR, Peet MM, Reitz AB, Negus SS, Rawls SM.

Br J Pharmacol. 2015 Feb;172(3):883-94. doi: 10.1111/bph.12951. Epub 2014 Dec 15.

25.

Alpha-ethyltryptamines as dual dopamine-serotonin releasers.

Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB.

Bioorg Med Chem Lett. 2014 Oct 1;24(19):4754-4758. doi: 10.1016/j.bmcl.2014.07.062. Epub 2014 Jul 29.

26.

Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics.

Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, Rothman RB.

ACS Med Chem Lett. 2014 Apr 15;5(6):623-7. doi: 10.1021/ml500113s. eCollection 2014 Jun 12.

27.

Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni').

Brandt SD, Baumann MH, Partilla JS, Kavanagh PV, Power JD, Talbot B, Twamley B, Mahony O, O'Brien J, Elliott SP, Archer RP, Patrick J, Singh K, Dempster NM, Cosbey SH.

Drug Test Anal. 2014 Jul-Aug;6(7-8):684-95. doi: 10.1002/dta.1668. Epub 2014 May 19.

28.

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB.

Psychopharmacology (Berl). 2014 Oct;231(21):4135-44. doi: 10.1007/s00213-014-3557-7. Epub 2014 May 7.

29.

Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.

Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, Negus SS.

Exp Clin Psychopharmacol. 2014 Jun;22(3):274-284. doi: 10.1037/a0036595. Epub 2014 May 5.

30.

Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).

Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH.

Neuropharmacology. 2014 Dec;87:206-13. doi: 10.1016/j.neuropharm.2014.02.016. Epub 2014 Mar 2.

31.

Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates.

Baumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS, Ali SF, Stockner T, Rothman RB, Sandtner W, Sitte HH.

Neuropsychopharmacology. 2014 May;39(6):1355-65. doi: 10.1038/npp.2013.331. Epub 2013 Nov 28.

32.

Psychoactive "bath salts": not so soothing.

Baumann MH, Partilla JS, Lehner KR.

Eur J Pharmacol. 2013 Jan 5;698(1-3):1-5. doi: 10.1016/j.ejphar.2012.11.020. Epub 2012 Nov 23. Review.

33.

Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.

Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH.

Eur J Pharmacol. 2013 Jan 15;699(1-3):180-7. doi: 10.1016/j.ejphar.2012.11.008. Epub 2012 Nov 21.

34.

Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW.

Neuropsychopharmacology. 2013 Mar;38(4):552-62. doi: 10.1038/npp.2012.204. Epub 2012 Oct 17.

35.

Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters.

Severinsen K, Kraft JF, Koldsø H, Vinberg KA, Rothman RB, Partilla JS, Wiborg O, Blough B, Schiøtt B, Sinning S.

ACS Chem Neurosci. 2012 Sep 19;3(9):693-705. Epub 2012 Jun 10.

36.

Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE.

J Pharmacol Exp Ther. 2012 Apr;341(1):251-62. doi: 10.1124/jpet.111.188946. Epub 2012 Jan 23.

37.

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV.

Neuropsychopharmacology. 2012 Apr;37(5):1192-203. doi: 10.1038/npp.2011.304. Epub 2011 Dec 14.

38.

Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Yubero-Lahoz S, Ayestas MA Jr, Blough BE, Partilla JS, Rothman RB, de la Torre R, Baumann MH.

Eur J Pharmacol. 2012 Jan 15;674(2-3):337-44. doi: 10.1016/j.ejphar.2011.10.033. Epub 2011 Nov 3.

39.

Evidence for noncompetitive modulation of substrate-induced serotonin release.

Rothman RB, Baumann MH, Blough BE, Jacobson AE, Rice KC, Partilla JS.

Synapse. 2010 Nov;64(11):862-9. doi: 10.1002/syn.20804.

40.

Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release.

Rothman RB, Dersch CM, Ananthan S, Partilla JS.

J Pharmacol Exp Ther. 2009 May;329(2):718-28. doi: 10.1124/jpet.108.149088. Epub 2009 Feb 24.

41.

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.

Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH.

J Pharmacol Exp Ther. 2009 May;329(2):738-46. doi: 10.1124/jpet.108.146142. Epub 2009 Feb 5.

42.

Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors.

Xu H, Wang X, Partilla JS, Bishop-Mathis K, Benaderet TS, Dersch CM, Simpson DS, Prisinzano TE, Rothman RB.

Brain Res Bull. 2008 Sep 5;77(1):49-54. doi: 10.1016/j.brainresbull.2008.05.003. Epub 2008 Jun 4.

43.

Evidence for a mu-delta opioid receptor complex in CHO cells co-expressing mu and delta opioid peptide receptors.

Rutherford JM, Wang J, Xu H, Dersch CM, Partilla JS, Rice KC, Rothman RB.

Peptides. 2008 Aug;29(8):1424-31. doi: 10.1016/j.peptides.2008.03.019. Epub 2008 Apr 8.

PMID:
18472184
44.

Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.

Pariser JJ, Partilla JS, Dersch CM, Ananthan S, Rothman RB.

J Pharmacol Exp Ther. 2008 Jul;326(1):286-95. doi: 10.1124/jpet.108.139675. Epub 2008 Apr 25.

45.

Herkinorin analogues with differential beta-arrestin-2 interactions.

Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE.

J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2.

46.

Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.

Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC.

J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.

PMID:
17625813
47.

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.

Simpson DS, Katavic PL, Lozama A, Harding WW, Parrish D, Deschamps JR, Dersch CM, Partilla JS, Rothman RB, Navarro H, Prisinzano TE.

J Med Chem. 2007 Jul 26;50(15):3596-603. Epub 2007 Jun 20.

PMID:
17580847
48.

A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.

Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, Rothman RB.

Synapse. 2007 Mar;61(3):166-75.

PMID:
17152090
49.

Salvinorin A: allosteric interactions at the mu-opioid receptor.

Rothman RB, Murphy DL, Xu H, Godin JA, Dersch CM, Partilla JS, Tidgewell K, Schmidt M, Prisinzano TE.

J Pharmacol Exp Ther. 2007 Feb;320(2):801-10. Epub 2006 Oct 23.

PMID:
17060492
50.

Interaction of amphetamines and related compounds at the vesicular monoamine transporter.

Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB.

J Pharmacol Exp Ther. 2006 Oct;319(1):237-46. Epub 2006 Jul 11.

PMID:
16835371

Supplemental Content

Loading ...
Support Center